Atsena Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for its gene therapy product candidate, ATSN-201, to treat X-linked retinoschisis (XLRS).

"We are pleased that the FDA has granted Fast Track designation to ATSN-201, reinforcing its potential to address the significant unmet need in XLRS, a rare inherited retinal disease with no approved ...

The shore was nowhere in sight, but DJ Pauly D brought his A-game to The Senate March 6, spinning with all ... Thursday night, the tunes came fast and furious. He spun snippets, samples and ...

The terminations are part of the department's 'final mission' it said, alluding to Trump's vow to eliminate the department, which oversees $1.6 trillion in college loans, enforces civil rights ...

It’s just about warm enough to take the winter tires off, but Murphy’s law dictates one last snowstorm as soon as you make the swap—as always, AutoGuide is here for it. We don’t always ...

Credit: megaflopp/Shutterstock. Atsena Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for its gene therapy product candidate, ATSN-201, to treat ...